<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02729532</url>
  </required_header>
  <id_info>
    <org_study_id>14-1697</org_study_id>
    <secondary_id>US NIH Grant P30 AI50410-17</secondary_id>
    <nct_id>NCT02729532</nct_id>
  </id_info>
  <brief_title>Effect of Xpert MTB/RIF on Patient Outcomes</brief_title>
  <official_title>Z 31411 - The Effect of Xpert MTB/RIF on Patient Health Outcomes and Empirical TB Treatment Among Persons Living With HIV/AIDS: A Parallel-Group Prospective Cohort Study Under Real-World Conditions in Lusaka, Zambia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A parallel-group prospective cohort study among adult persons living with HIV/AIDS to study
      the effect of a new TB diagnostic test, Xpert MTB/RIF on: 1) TB case detection; 2) time to TB
      diagnosis and TB treatment; 3) presumptive TB patient drop-out from the TB diagnostic
      &quot;cascade&quot; before starting TB treatment; and 4) loss to follow-up after initiation of TB
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Centre for Infectious Disease Research in Zambia (CIDRZ) in collaboration with the
      Zambian National TB Program (NTP) and the Ministry of Health (MOH) will provide near
      point-of-care Xpert testing at a high-volume anti-retroviral treatment (ART) clinic in
      Lusaka, Zambia. A total 892 study participants will be enrolled into two parallel cohorts—an
      &quot;Xpert&quot; and a &quot;standard of care&quot; (SOC) cohort over a 7-month period. The Xpert cohort will
      enrol participants at the health centre implementing Xpert. The SOC cohort will enrol
      participants from one health centre offering the standard of care (sputum smear microscopy
      plus clinical evaluation). A parallel-group prospective cohort study will be conducted by
      following participants in one cohort from each site for 210 days from the time of sputum
      submission, allowing sufficient person-time to observe all outcomes of interest, including
      completion of a standard course of ATT as well as patient drop-out and loss to follow-up.

      A systematic facility assessment survey using an adapted version of the WHO Service
      Availability and Readiness Assessment tool will be conducted. Key informants will be
      interviewed.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 22, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Culture-positive patient drop-out before accessing treatment</measure>
    <time_frame>From study enrolment through confirmed drop out date at or before 210-days post enrollment</time_frame>
    <description>For both cohorts, the proportion of patients not started on TB treatment by 210 days post-enrolment will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to TB treatment</measure>
    <time_frame>time in days from study enrolment to initiation of anti-TB therapy (ATT) (through 210 days post-enrolment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who receive TB treatment within 14 days of enrolment (effect of Xpert on the accuracy of TB diagnosis)</measure>
    <time_frame>study enrolment to 14 days of enrolment</time_frame>
    <description>sensitivity of empirical TB diagnosis and treatment will be defined as the percentage of participants who received TB treatment within 14 days of enrolment among all those with a positive culture but negative or unavailable result for SM (for the SOC cohort), or negative or unavailable SM plus Xpert (for the Xpert cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who did not receive TB treatment 14 days post-enrolment (effect of Xpert on the accuracy of TB diagnosis)</measure>
    <time_frame>study enrolment to 14 days of enrolment</time_frame>
    <description>the specificity of empirical treatment will be defined as the percentage of participants who did not receive TB treatment 14 days post-enrolment among all those with a negative culture and negative or unavailable result for SM (in the SOC cohort), or negative or unavailable result for SM plus Xpert (in the Xpert cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to TB Diagnosis</measure>
    <time_frame>average of 28 days</time_frame>
    <description>The World Health Organization definition of a TB case will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of TB patients lost to follow-up</measure>
    <time_frame>The number of patients will be measured as time in days from study enrolment to confirmed drop out (confirmed as failure noted at 3 and 6 month chart review)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">892</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Xpert cohort</arm_group_label>
    <description>HIV-positive presumptive TB patients tested for TB using Xpert MTB/RIF assay (fluorescence microscopy and TB culture also done to serve as reference standard)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care cohort</arm_group_label>
    <description>HIV-positive presumptive TB patients tested for TB using standard of care testing (sputum smear microscopy plus clinical evaluation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xpert</intervention_name>
    <description>The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System</description>
    <arm_group_label>Xpert cohort</arm_group_label>
    <other_name>Xpert MTB/RIF assay</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult presumptive TB patients 18 years or older with documented HIV-positive sero-status
        presenting for routine HIV care at two health centres in Lusaka, Zambia.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to spontaneously expectorate at least 2 sputum samples, in accordance with NTP
             guidelines

          -  Intend to continue receiving care at the respective study sites for at least 7 months

          -  Willing to provide locator information and allow contact by phone or home visit in the
             case of loss to follow up after initiating ATT

        Exclusion Criteria:

          -  Received TB treatment within 60 days prior to enrolment and/or were diagnosed with TB
             within the last 6 months

          -  Cannot spontaneously expectorate sputum

          -  Are already enrolled in another study with might interfere with implementation of this
             study protocol

          -  Provided a sputum sample that results in a contaminated TB culture result

        A key informant will be eligible for inclusion in the SARA facility survey component of the
        study if they meet the following criteria:

          -  18 years of age or older

          -  clinic staff member at either Chilenje Health Centre or Chelstone Health Centre

          -  have previously been attached to, or are otherwise familiar with, departments offering
             HIV, TB and/or laboratory health services

        Exclusion criteria:

        -unwilling or unable to provide verbal informed consent in English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Herce, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chelstone and Chilenje Health Centres</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <link>
    <url>http://www.unc.edu</url>
    <description>University of North Carolina website</description>
  </link>
  <reference>
    <citation>Botha E, Den Boon S, Verver S, Dunbar R, Lawrence KA, Bosman M, Enarson DA, Toms I, Beyers N. Initial default from tuberculosis treatment: how often does it happen and what are the reasons? Int J Tuberc Lung Dis. 2008 Jul;12(7):820-3.</citation>
    <PMID>18544210</PMID>
  </reference>
  <reference>
    <citation>World Health Organization. (2013). Global tuberculosis report 2013. Geneva: WHO.</citation>
  </reference>
  <reference>
    <citation>Millen SJ, Uys PW, Hargrove J, van Helden PD, Williams BG. The effect of diagnostic delays on the drop-out rate and the total delay to diagnosis of tuberculosis. PLoS One. 2008 Apr 9;3(4):e1933. doi: 10.1371/journal.pone.0001933.</citation>
    <PMID>18398459</PMID>
  </reference>
  <reference>
    <citation>Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010 Sep 9;363(11):1005-15. doi: 10.1056/NEJMoa0907847. Epub 2010 Sep 1.</citation>
    <PMID>20825313</PMID>
  </reference>
  <reference>
    <citation>Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011 Apr 30;377(9776):1495-505. doi: 10.1016/S0140-6736(11)60438-8. Epub 2011 Apr 18.</citation>
    <PMID>21507477</PMID>
  </reference>
  <reference>
    <citation>Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, Bekker LG, Wood R. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med. 2011 Jul;8(7):e1001067. doi: 10.1371/journal.pmed.1001067. Epub 2011 Jul 26.</citation>
    <PMID>21818180</PMID>
  </reference>
  <reference>
    <citation>Boehme, C. C. Oral Presentation, 20th Conference on Retroviruses and Opportunistic Infections. Georgia World Conference Centre, Atlanta, USA, March 3-6, 2013.</citation>
  </reference>
  <reference>
    <citation>Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K; TB-NEAT team. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014 Feb 1;383(9915):424-35. doi: 10.1016/S0140-6736(13)62073-5. Epub 2013 Oct 28.</citation>
    <PMID>24176144</PMID>
  </reference>
  <reference>
    <citation>Office of the U.S. Global AIDS Coordinator. Scaling Up TB Prevention, Screening, Diagnosis and Care in Zambia: Implementing the WHO 3I's, Program Protocol. Lusaka: Centers for Disease Control and Prevention—Zambia, 2012.</citation>
  </reference>
  <reference>
    <citation>Kivihya-Ndugga LE, van Cleeff MR, Githui WA, Nganga LW, Kibuga DK, Odhiambo JA, Klatser PR. A comprehensive comparison of Ziehl-Neelsen and fluorescence microscopy for the diagnosis of tuberculosis in a resource-poor urban setting. Int J Tuberc Lung Dis. 2003 Dec;7(12):1163-71.</citation>
    <PMID>14677891</PMID>
  </reference>
  <reference>
    <citation>UNAIDS. Global Report: UNAIDS report on the global AIDS epidemic 2013. Geneva: Joint United Nations Programme on HIV/AIDS, 2013.</citation>
  </reference>
  <reference>
    <citation>Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet. 2007 Jun 16;369(9578):2042-9. Review.</citation>
    <PMID>17574096</PMID>
  </reference>
  <reference>
    <citation>Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, Urbanczik R, Perkins M, Aziz MA, Pai M. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006 Sep;6(9):570-81. Review. Erratum in: Lancet Infect Dis. 2006 Oct;6(10):628.</citation>
    <PMID>16931408</PMID>
  </reference>
  <reference>
    <citation>Sreeramareddy CT, Panduru KV, Menten J, Van den Ende J. Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infect Dis. 2009 Jun 11;9:91. doi: 10.1186/1471-2334-9-91. Review.</citation>
    <PMID>19519917</PMID>
  </reference>
  <reference>
    <citation>Cohen T, Murray M, Wallengren K, Alvarez GG, Samuel EY, Wilson D. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med. 2010 Jun 22;7(6):e1000296. doi: 10.1371/journal.pmed.1000296.</citation>
    <PMID>20582324</PMID>
  </reference>
  <reference>
    <citation>Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, Davis JL, Whitelaw A, Nicol MP, Gler MT, Khaliqov A, Zamudio C, Perkins MD, Boehme CC, Cobelens F. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med. 2011 Nov;8(11):e1001120. doi: 10.1371/journal.pmed.1001120. Epub 2011 Nov 8.</citation>
    <PMID>22087078</PMID>
  </reference>
  <reference>
    <citation>Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD009593. doi: 10.1002/14651858.CD009593.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(1):CD009593.</citation>
    <PMID>23440842</PMID>
  </reference>
  <reference>
    <citation>Dowdy DW, Davis JL, den Boon S, Walter ND, Katamba A, Cattamanchi A. Population-level impact of same-day microscopy and Xpert MTB/RIF for tuberculosis diagnosis in Africa. PLoS One. 2013 Aug 12;8(8):e70485. doi: 10.1371/journal.pone.0070485. eCollection 2013.</citation>
    <PMID>23950942</PMID>
  </reference>
  <reference>
    <citation>Van Rie A, Page-Shipp L, Hanrahan CF, Schnippel K, Dansey H, Bassett J, Clouse K, Scott L, Stevens W, Sanne I. Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa. Int J Tuberc Lung Dis. 2013 Mar;17(3):368-72. doi: 10.5588/ijtld.12.0392.</citation>
    <PMID>23407225</PMID>
  </reference>
  <reference>
    <citation>Hanrahan CF, Selibas K, Deery CB, Dansey H, Clouse K, Bassett J, Scott L, Stevens W, Sanne I, Van Rie A. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One. 2013 Jun 6;8(6):e65421. doi: 10.1371/journal.pone.0065421. Print 2013.</citation>
    <PMID>23762367</PMID>
  </reference>
  <reference>
    <citation>Clouse K, Page-Shipp L, Dansey H, Moatlhodi B, Scott L, Bassett J, Stevens W, Sanne I, Van Rie A. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J. 2012 Sep 7;102(10):805-7. doi: 10.7196/samj.5851.</citation>
    <PMID>23034211</PMID>
  </reference>
  <reference>
    <citation>Lawn SD, Ayles H, Egwaga S, Williams B, Mukadi YD, Santos Filho ED, Godfrey-Faussett P, Granich RM, Harries AD. Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. Int J Tuberc Lung Dis. 2011 Mar;15(3):287-95.</citation>
    <PMID>21333094</PMID>
  </reference>
  <reference>
    <citation>Yoon C, Cattamanchi A, Davis JL, Worodria W, den Boon S, Kalema N, Katagira W, Kaswabuli S, Miller C, Andama A, Albert H, Nabeta P, Gray C, Ayakaka I, Huang L. Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS One. 2012;7(11):e48599. doi: 10.1371/journal.pone.0048599. Epub 2012 Nov 6.</citation>
    <PMID>23139799</PMID>
  </reference>
  <reference>
    <citation>Global Health Workforce Statistics, World Health Organization, Geneva. Accessed online at: http://www.who.int/hrh/statistics/hwfstats/ on November 24, 2013.</citation>
  </reference>
  <reference>
    <citation>WHO. Guidelines for intensified tuberculosis case-finding and isoniazid preventative therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization, 2011.</citation>
  </reference>
  <reference>
    <citation>WHO. Treatment of tuberculosis guidelines, 4th edition. Geneva: World Health Organization, 2010.</citation>
  </reference>
  <reference>
    <citation>Global Laboratory Initiative. Laboratory diagnosis of tuberculosis by sputum microscopy: The handbook. Geneva: Global Laboratory Initiative, 2013.</citation>
  </reference>
  <reference>
    <citation>Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999 Aug 15;150(4):327-33. Review.</citation>
    <PMID>10453808</PMID>
  </reference>
  <reference>
    <citation>WHO/TDR/FIND. Diagnostics for tuberculosis: Global demand and market potential. Geneva: World Health Organization, 2006.</citation>
  </reference>
  <reference>
    <citation>Balcha TT, Sturegård E, Winqvist N, Skogmar S, Reepalu A, Jemal ZH, Tibesso G, Schön T, Björkman P. Intensified tuberculosis case-finding in HIV-positive adults managed at Ethiopian health centers: diagnostic yield of Xpert MTB/RIF compared with smear microscopy and liquid culture. PLoS One. 2014 Jan 22;9(1):e85478. doi: 10.1371/journal.pone.0085478. eCollection 2014.</citation>
    <PMID>24465572</PMID>
  </reference>
  <reference>
    <citation>Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infect Dis. 2014 Jun;14(6):527-32. doi: 10.1016/S1473-3099(13)70360-8. Epub 2014 Jan 15.</citation>
    <PMID>24438820</PMID>
  </reference>
  <reference>
    <citation>Conwell DS, Mosher A, Khan A, Tapy J, Sandman L, Vernon A, Horsburgh CR Jr. Factors associated with loss to follow-up in a large tuberculosis treatment trial (TBTC Study 22). Contemp Clin Trials. 2007 May;28(3):288-94. Epub 2006 Sep 28.</citation>
    <PMID>17107825</PMID>
  </reference>
  <reference>
    <citation>Henostroza G, Harris J, Siyambango M, et al. High prevalence of tuberculosis among new HIV care enrolees in Zambia: urgent need for an enhanced screening approach. Oral presentation, 43rd World Conference on Lung Health. Kuala Lumpur Convention Centre, Kuala Lumpur, Malaysia. November 13 - 17, 2012.</citation>
  </reference>
  <reference>
    <citation>Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004 Apr 1;159(7):702-6.</citation>
    <PMID>15033648</PMID>
  </reference>
  <reference>
    <citation>Chang K, Lu W, Wang J, Zhang K, Jia S, Li F, Deng S, Chen M. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect. 2012 Jun;64(6):580-8. doi: 10.1016/j.jinf.2012.02.012. Epub 2012 Feb 27.</citation>
    <PMID>22381459</PMID>
  </reference>
  <reference>
    <citation>Moure R, Martín R, Alcaide F. Effectiveness of an integrated real-time PCR method for detection of the Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples in an area of low tuberculosis prevalence. J Clin Microbiol. 2012 Feb;50(2):513-5. doi: 10.1128/JCM.06467-11. Epub 2011 Dec 7.</citation>
    <PMID>22162564</PMID>
  </reference>
  <reference>
    <citation>Ministry of Health, Republic of Zambia. Managing Tuberculosis in the HIV Setting in Zambia. Lusaka: Ministry of Health, 2014.</citation>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extra-pulmonary tuberculosis</keyword>
  <keyword>multiple drug resistant tuberculosis</keyword>
  <keyword>mycobacterium tuberculosis</keyword>
  <keyword>human immunodeficiency virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

